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Introduction
An estimated one third of the world’s population has latent 
tuberculosis infection and in 2015 10.4 million people de-
veloped tuberculosis disease.1 Those at the highest risk of 
tuberculosis include the household contacts of patients with 
the disease and people living in poverty.2 Trials have shown 
that preventive therapy decreases the risk of progression to 
tuberculosis disease by 60 to 90%.2–4 Nevertheless, globally the 
impact of preventive therapy on tuberculosis control is limited 
because people with a latent tuberculosis infection are seldom 
identified5 and, therefore, seldom take preventive therapy.6–9 In 
addition, many people have difficulty adhering to treatment7,8,10 
and tuberculosis patients who do not take adequate treatment 
are more likely to experience adverse outcomes, such as treat-
ment failure, tuberculosis recurrence and death.11 They are also 
more likely to transmit the infection, especially to household 
contacts12 and to develop multidrug-resistant tuberculosis,13 
an increasing global public health threat.5
The current, predominantly biomedical approach to tu-
berculosis control is not reducing disease incidence to the level 
required to eliminate tuberculosis envisioned in the World 
Health Organization’s (WHO) End TB Strategy.14,15 Increas-
ing access to tuberculosis preventive therapy and treatment is 
likely to improve disease prevention and treatment success but 
requires strategies complementary to biomedical care, includ-
ing socioeconomic support. Interventions such as conditional 
cash transfers can help improve people’s capacity to manage 
social and financial risks.16–23 Although socioeconomic inter-
ventions are common in the treatment of human immunodefi-
ciency virus infection (HIV) and acquired immune deficiency 
syndrome (AIDS) and in maternal health,24,25 little is known 
about their impact on tuberculosis care or prevention.16,18,19,26
Our research group in Peru, Innovation for Health and 
Development, has been funded to undertake the Community 
Randomized Evaluation of a Socioeconomic Intervention to 
Prevent TB (CRESIPT) project. The planning, design and eco-
nomic impact of the intervention have been described previ-
ously.27,28 Here we report the final results of the initial phase of 
CRESIPT, which involved a household-randomized, controlled 
study that evaluated the impact of tuberculosis-specific socio-
economic support on the initiation of tuberculosis preventive 
therapy and on tuberculosis treatment success. In addition, we 
describe the refinement of this intervention used in CRESIPT.
Methods
The study evaluated the impact of a socioeconomic support 
intervention – described in Box 1 – in 32 contiguous shanty 
towns in Callao, Peru, the northern, coastal extension of the 
Objective To evaluate the impact of socioeconomic support on tuberculosis preventive therapy initiation in household contacts of 
tuberculosis patients and on treatment success in patients.
Methods A non-blinded, household-randomized, controlled study was performed between February 2014 and June 2015 in 32 shanty 
towns in Peru. It included patients being treated for tuberculosis and their household contacts. Households were randomly assigned to either 
the standard of care provided by Peru’s national tuberculosis programme (control arm) or the same standard of care plus socioeconomic 
support (intervention arm). Socioeconomic support comprised conditional cash transfers up to 230 United States dollars per household, 
community meetings and household visits. Rates of tuberculosis preventive therapy initiation and treatment success (i.e. cure or treatment 
completion) were compared in intervention and control arms.
Findings Overall, 282 of 312 (90%) households agreed to participate: 135 in the intervention arm and 147 in the control arm. There were 
410 contacts younger than 20 years: 43% in the intervention arm initiated tuberculosis preventive therapy versus 25% in the control arm 
(adjusted odds ratio, aOR: 2.2; 95% confidence interval, CI: 1.1–4.1). An intention-to-treat analysis showed that treatment was successful 
in 64% (87/135) of patients in the intervention arm versus 53% (78/147) in the control arm (unadjusted OR: 1.6; 95% CI: 1.0–2.6). These 
improvements were equitable, being independent of household poverty.
Conclusion A tuberculosis-specific, socioeconomic support intervention increased uptake of tuberculosis preventive therapy and 
tuberculosis treatment success and is being evaluated in the Community Randomized Evaluation of a Socioeconomic Intervention to 
Prevent TB (CRESIPT) project.
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capital Lima (Fig. 1). The Province of 
Callao has a population of 1 million, 
considerable poverty and zones with 
high levels of drug addiction and gun 
crime. The annual tuberculosis case 
notification rate in 2014 was 123 new 
cases per 100 000 population, the highest 
rate in the country.34
The study included the households 
of patients starting treatment for tu-
berculosis disease administered by the 
Peruvian National Tuberculosis Pro-
gramme. The invitation to participate 
was accompanied by a written informed 
consent form that explained the ran-
domization process. Patients completed 
the form on the household’s behalf. 
For minors, a parent or guardian gave 
consent with the patient’s assent. We 
only included consenting households. 
Individuals reported by the patient 
during a household visit to have been in 
the same house as the patient for over 
6 hours per week in the 2 weeks before 
tuberculosis was diagnosed, were iden-
tified and validated and are henceforth 
described as contacts. Contacts declared 
or discovered following randomization 
(but not during initial recruitment) were 
not included in the analysis and were not 
invited to participate in the study.
Subsequently, patients’ households 
were randomly assigned on a 1:1 ratio 
to either: (i) the control arm, in which 
households received the standard of 
care provided by the Peruvian National 
TB Programme; or (ii) the intervention 
arm, in which households additionally 
received the integrated socioeconomic 
support package. Randomization was 
performed using random number 
tables, which generated individual 
household randomization sequences 
for each health post. Once a patient 
gave informed consent, a project nurse 
opened a numbered, sealed envelope 
that contained the study allocation and 
revealed the allocation to the patient. 
It was not feasible to blind households 
or the research team to the allocation. 
However, staff members from the na-
tional tuberculosis programme were not 
informed and were generally unaware of 
a household’s allocation but they were 
not confirmed as being blinded.
Data on health, well-being and so-
ciodemographic characteristics, including 
height, weight, body mass index and socio-
economic position, were collected using a 
locally validated questionnaire at baseline 
(i.e. at the start of tuberculosis treatment) 
and again 24 weeks later, or 28 weeks later if 
treatment was prolonged, due, for example, 
to suboptimal treatment adherence.6,27,29
Treatment
For the contacts of patients with pul-
monary tuberculosis that was not 
caused by multidrug-resistant bacte-
ria, Peruvian National Tuberculosis 
Programme guidelines, which were 
applied throughout the study, recom-
mended that preventive therapy should 
be: (i) provided for all contacts younger 
than 5 years, unless the contact is known 
to have previously had tuberculosis 
disease, without tuberculin skin testing; 
and (ii) considered for all contacts aged 
5 to 19 years with a positive tuberculin 
skin test result.29 However, tuberculin 
was generally unavailable throughout 
the study. Preventive therapy consisted 
of a 6-month course of daily isoniazid, 
which contacts collected weekly from 
health posts and took unsupervised at 
home.29 Data on preventive therapy ini-
tiation, adherence and completion were 
obtained from the Peruvian National TB 
Programme records and included the 
number of weeks of preventive therapy 
collected (hereafter defined as preven-
tive therapy taken) from the health post 
for each household contact.
The Peruvian National TB Pro-
gramme offered free tuberculosis di-
agnostic testing to all people with 
symptoms suggestive of tuberculosis. 
If diagnosed with the disease, they re-
ceived free anti-tuberculosis treatment 
at the health post under the directly-
observed-treatment (DOTS) strategy.29 
In addition, all patients, regardless of 
their allocation, were offered a sputum 
test with Xpert MTB/RIF (Cepheid, 
Sunnyvale, United States of America) 
at our research laboratory for rapid ri-
fampicin susceptibility testing – this test 
was not otherwise routinely available.
Outcomes
The primary study outcome was initia-
tion of tuberculosis preventive therapy 
Box 1. Description of the socioeconomic support intervention for tuberculosis 
prevention and treatment, Peru, 2014–2015
The socioeconomic support intervention comprised an integrated package of social and 
economic support.27 The intervention targeted outcomes on the tuberculosis causal pathway 
and promoted equitable access to tuberculosis programme activities, including: (i) screening 
for tuberculosis in contacts of patients; (ii) the initiation of tuberculosis preventive therapy 
and completion of tuberculosis treatment; and (iii) engagement with social support activities.
Social support comprised household visits and participatory community meetings that aimed to 
provide information and mutual support, empowerment and reduce the stigma of tuberculosis. 
Household visits were made shortly after the patient commenced treatment and involved 
providing education on tuberculosis transmission, treatment and preventive therapy and on 
household finances. Community meetings took place monthly and were each attended by 
around 15 patients and their household contacts. They cost around 189 United States dollars (US$) 
each (approximately US$ 13 per patient per meeting).27 The meetings reinforced the educational 
themes of the household visits and established tuberculosis clubs, in which participants could 
share their tuberculosis-related experiences in a mutually supportive group (to be reported 
elsewhere). All household members were invited and encouraged to participate in household 
visits and community meetings.
Economic support comprised making conditional cash transfers throughout treatment to defray 
average household tuberculosis-associated costs, thereby reducing risk factors for tuberculosis 
while also incentivizing and enabling care. Economic support was designed to ensure direct 
out-of-pocket expenses would be completely defrayed for patients who received all conditional 
cash transfers. Previously, such direct out-of-pocket expenses had been found to be 10% of annual 
household income in the study setting,29 equivalent to approximately US$ 230. We hypothesized 
that defraying these direct expenses would decrease the tuberculosis-affected household’s 
financial burden, decrease the likelihood of incurring catastrophic costs and, when combined 
with integrated social support, enhance access to tuberculosis care and improve tuberculosis 
outcomes. During the planning of the intervention it was estimated that, if the intervention 
were implemented nationally, the budget of the Peruvian National Tuberculosis Programme 
would have to increase by approximately 15% per patient.29 Focus group discussions with 
key stakeholders suggested that such an increase was locally appropriate and affordable.27,29,30 
Moreover, a review of the relevant literature suggested that interventions that increased the 
per-patient cost of a tuberculosis programme budget by 50% or less and that reduced the 
incidence of tuberculosis by at least one third were likely to be cost-effective and sustainable.31,32
The socioeconomic support intervention was informed by the findings of our group’s Innovative 
Socioeconomic Interventions Against TB (ISIAT) study,6 two systematic reviews of cash-transfer 
interventions,16,27 expert consultations18 and feedback from civil society and leaders of the 
Peruvian National Tuberculosis Programme.27
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by a contact younger than 20 years who 
was available for follow-up. The sec-
ondary study outcome was successful 
tuberculosis treatment of a patient with 
the disease, which was assessed on an 
intention-to-treat basis and included 
patients with unknown outcomes. 
Successful tuberculosis treatment was 
defined as either a cure or completed 
treatment. In accordance with WHO 
definitions,1 the Peruvian National TB 
Programme guidelines regarded patients 
with bacteriologically confirmed, drug-
susceptible tuberculosis at diagnosis as 
having been cured if they: (i) completed 
treatment; (ii) had a negative sputum 
smear test result during the final month 
of treatment; and (iii) had received 
a favourable clinical assessment by a 
national programme physician who 
had evaluated their symptoms, per-
formed an examination, weighed them 
and, when necessary, carried out chest 
radiography and blood tests.29 Patients 
were regarded as having completed tu-
berculosis treatment if they completed 
the treatment course without evidence 
of failure, even if they did not undergo 
the required sputum testing or physician 
review. Other outcomes consistent with 
WHO guidance were: (i) death due to 
any cause before or during tuberculosis 
treatment; (ii) treatment failure (i.e. 
positive sputum microscopy or culture 
findings after 5 months of treatment or 
later); and (iii) lost to follow-up, which 
included patients whose treatment was 
interrupted for at least 30 consecutive 
days or who discontinued treatment 
having been treated for less than 30 days 
– this is shorter than the 2-month or lon-
ger interruption in WHO’s definition. 
Treatment outcome data were collected 
from each patient’s treatment card at the 
final follow-up in collaboration with the 
Peruvian National TB Programme and 
were not influenced by this research. 
Outcomes could not be assessed in pa-
tients whose treatment outcome had not 
been assigned, such as those who had 
been transferred to another treatment 
unit and those who were still on treat-
ment at the 28-week follow-up interview 
(e.g. patients with multidrug-resistant 
tuberculosis, who are often treated for 
24 months). The study was approved by 
the ethics committees of the Regional 
Ministry of Health in Callao, Asociación 
Benéfica Prisma in Peru, and Imperial 
College London, United Kingdom of 
Great Britain and Northern Ireland.
Statistical analysis
Sample size calculations indicated that 
a study including 400 contacts would 
have 80% statistical power to detect a 
50% increase in the primary outcome 
in intervention households compared 
with control households with a two-
sided 5% level of significance.6 We 
assessed differences in treatment suc-
cess and preventive therapy initiation 
Fig. 1. Study area and participants, study of the effect of socioeconomic support on tuberculosis prevention and treatment, Peru, 
2014–2015
District and 
health post
Community 
population
Study 
participants
North Ventanilla
1. Luis Felipe de las Casa 19  984 26
2. 3 de Febrero 26  919 65
3. Villa Los Reyes 30  571 111
4. Bahía Blanca 17 132 57
5. Peru Korea Pachacutec 42 287 85
6. Pachacutec 12 582 97
7. Defensores de la Patria 45 052 25
South Ventanilla
8. Santa Rosa Pachacutec 23 749 93
9. Mi Perú 56 315 156
10. Ventanilla Alta 33 791 29
11. Hijos de Grau 30 571 32
12. Angamos 54 706 36
13. Ventanilla Baja 6 468 0
14. Ventanilla Este 8 013 21
15. Márquez 12 665 73
North Callao
16. Palmeras de Oquendo 14 612 40
17. Acapulco 21 918 71
18. El Alamo 20 295 0
19. Sesquicentenario 41 644 11
20. Preví 12 948 2
21. Polígono IV 11 893 42
22. Bocanegra 18 265 27
23. Villa Señor de los Milagros 14 324 35
24. Peru Korea Bellavista 72 665 109
South Callao
25. Néstor Gambeta 20 903 100
26. Callao 23 298 15
27. Santa Fé 17 453 10
28. Jose Boterín 11 608 45
29. Alberto Barton 29 427 53
30. Manuel Bonilla 32 471 64
31. La Perla 24 966 36
32. Alta Mar 34 552 13
TOTAL 844 047 1579
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Peru
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Note: The map of Peru is from Wikimedia Commons and is licensed under the Creative Commons Attribution-Share Alike 3.0 Unported license.33
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rates between the study groups using 
univariable logistic regression analysis 
and, in the case of treatment success, 
also by multivariable logistic regression 
analysis to adjust for household cluster-
ing. The level of household poverty was 
determined by combining socioeco-
nomic variables into a composite index 
using principal component analysis, as 
previously described.29 The significance 
of the difference in the duration of 
preventive therapy taken by contacts 
younger than 20 years in intervention 
and control households was assessed 
using the Mann–Whitney U test and by 
time-to-event analysis, which generated 
an unadjusted log-rank P-value.
Results
Recruitment commenced on 10 Febru-
ary 2014, the target sample size was 
reached on 14 August 2014 and follow-
up was completed on 1 June 2015. In 
total, we invited 312 households of 
patients with tuberculosis to participate 
and we recruited 90% (282/312), of 
which we randomized 135 households 
to the intervention arm and 147 to the 
control arm. Overall, 9% (24/282) of 
patients had multidrug-resistant tuber-
culosis, none of whom completed treat-
ment during the study. Patients from the 
282 recruited households had a total 
of 1297 contacts (mean: 4.6 contacts 
per household). Of the contacts, 40% 
(518/1297) were younger than 20 years 
and 79% (410/518) of this age group 
completed follow-up (Fig. 2). There 
was no substantive imbalance between 
households randomized to intervention 
or control arms in any sociodemograph-
ic characteristic (Table 1).
During the study, 90% (122/135) 
of households in the intervention arm 
received at least one conditional cash 
transfer. A total of 890 conditional cash 
transfers were made (i.e. 80% of all pos-
sible conditional cash transfers) – the 
average total received per household 
was 520 Peruvian soles (186 United 
States dollars, US$) out of a maximum 
available per household of 640 Peruvian 
soles (US$ 230).27,29
The proportion of contacts younger 
than 20 years who initiated tuberculosis 
preventive therapy was 44% (91/206) in 
the intervention arm and 26% (53/204) 
in the control arm. The difference was 
significant, both in the univariable 
analysis (odds ratio, OR: 2.2; 95% con-
fidence interval, CI: 1.4–3.3) and the 
multivariable analysis (adjusted odds 
ratio, aOR: 2.2; 95% CI: 1.1–4.1), which 
adjusted for household clustering. In the 
intention-to-treat analysis of treatment 
success in patients, the success rate was 
64% (87/135) in the intervention arm 
and 53% (78/147) in the control arm. The 
difference was significant in the univari-
able analysis (OR: 1.6; 95% CI: 1.0–2.6). 
An adjusted analysis was not relevant 
because there was only one patient per 
household. In addition, the proportion 
of patients from intervention house-
holds who were cured was significantly 
greater than the proportion from control 
households: 53% (71/135) versus 37% 
(55/147), respectively (P = 0.02). Details 
of the proportions who were cured or 
achieved other treatment outcomes as 
defined by WHO are reported in Table 2.
The greater use of preventive ther-
apy by contacts younger than 20 years 
in the intervention arm was maintained 
throughout the recommended 24 weeks 
of treatment. Among those who initiated 
preventive therapy, the mean duration 
of treatment was similar in intervention 
and control arms: 18 weeks (standard 
deviation, SD: 7.7) versus 18 weeks 
(SD: 7.8), respectively (P = 0.9). Conse-
quently, because more contacts initiated 
tuberculosis preventive therapy in the 
intervention arm, the mean duration of 
preventive therapy was significantly lon-
ger in the intervention than the control 
arm: 7.8 weeks (SD: 10) versus 4.8 weeks 
(SD: 8.9), respectively (P = 0.002). Time-
to-event analysis confirmed that the 
intervention was associated with greater 
overall preventive therapy initiation 
(log-rank P = 0.005; Fig. 3). As the study 
sample size was selected to test for the 
effect of the intervention on the whole 
study population, the study did not have 
sufficient statistical power to test for ef-
fects in subgroups. Thus, although the 
rate of preventive therapy completion 
was almost double in the intervention 
arm (20%; 95% CI: 14–25) than the 
control arm (12%; 95% CI: 7–16), the 
difference in this minority of the study 
population was significant only in the 
univariable analysis (OR: 1.9; 95% CI: 
1.1–3.2) but not in the adjusted analysis 
(aOR: 1.9; 95% CI: 0.78–4.5).
To assess the equity of the interven-
tion, we compared study outcomes in 
the most and least vulnerable subpopu-
lations. We compared treatment success 
and preventive therapy initiation rates 
Fig. 2. Flowchart, study of the effect of socioeconomic support on tuberculosis 
prevention and treatment, Peru, 2014–2015
312 households of patients with tuberculosis 
invited to participate
282 households recuited, with 1297 household 
contacts, of whom 518 were younger than 20 years
135 patients and 647 contacts, of whom 
260 were younger than 20 years
54 contacts aged 
under 20 years did 
not complete 
follow-up
54 contacts aged 
under 20 years did 
not complete 
follow-up
4 patients died prior 
to completing recruitment
26 patients declined to 
participate
147 patients and 650 contacts, of whom 
258 were aged under 20 years
135 patients and 206 contacts 
younger than 20 years who completed 
the final follow-up
147 patients and 204 contacts 
younger than 20 years who completed 
final follow-up
Randomization
Socioeconomic intervention Control arm
Secondary 
analysis 
of treatment 
success 
in patients
Primary analysis 
of initiation of 
preventive 
therapy in 
contacts
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in the poorest tercile of the population 
with the remaining population and 
compared preventive therapy initiation 
in child contacts younger than 5 years 
with contacts aged 5 to 19 years. Table 2 
demonstrates that the intervention was 
associated with an increase in the treat-
ment success rate in both poorer and 
less-poor subgroups and Fig. 4 shows it 
was associated with an increase in pre-
ventive therapy initiation in poorer and 
less-poor subgroups and in younger and 
older contact age groups. Furthermore, 
the intervention significantly increased 
preventive therapy initiation in contacts 
younger than 5 years (aOR: 2.2; 95% CI: 
1.1–4.2) and in the poorest tercile (aOR: 
2.2; 95% CI: 1.1–4.1). After adjusting 
for poverty group, the intervention was 
associated with a nonsignificant trend 
towards a greater likelihood of treatment 
success (aOR: 1.7; P = 0.07).
Discussion
Previous assessments of interventions 
for improving tuberculosis prevention 
or treatment adherence have been lim-
ited by a lack of randomization, by small 
sample sizes or by being conducted in 
high-resource settings within restricted 
patient groups, such as HIV-infected 
people,35 homeless people,36 migrants37 
or injecting drug users.2,38 Recent sys-
tematic reviews concluded there was no 
evidence that incentives, including cash 
transfers, improved tuberculosis preven-
tive therapy completion rates39 and there 
was little evidence to guide WHO rec-
ommendations on the implementation 
and scale-up of tuberculosis-specific, 
socioeconomic support in resource-
constrained settings.40 Our study, which 
found that a tuberculosis-specific, 
socioeconomic support intervention 
increased both the uptake of preventive 
therapy and the success of treatment, 
helps to fill this evidence gap.6,41
The management of household 
contacts of tuberculosis patients has 
been complicated by the current world-
wide shortage of tuberculin and the 
expense, technical complexity and lack 
of availability of commercial interferon-
gamma release assays.42 Despite the 
presence of these obstacles in Peru, our 
socioeconomic support intervention 
approximately doubled the tuberculo-
sis preventive therapy initiation rate. 
Moreover, because the protective effect 
of preventive therapy increases with its 
duration,3,4 our finding that the inter-
vention increased the number of weeks 
of tuberculosis preventive therapy taken 
is important, given that nonadherence 
is common,8,43,44 and could decrease the 
rate of secondary tuberculosis disease. 
Table 1. Baseline characteristics, study of the effect of socioeconomic support on tuberculosis prevention and treatment, Peru, 
2014–2015
Characteristics Intervention households 
(n = 135)
Control households 
(n = 147)
All households (n = 282)
All household contacts
Number of contacts identified per household, mean (SD) 4.9 (2.9) 4.4 (2.9) 4.6 (2.9)
Number of contacts aged < 20 years identified per 
household, mean (SD)
1.9 (1.7) 1.7 (1.7) 1.8 (1.7)
Contacts aged < 20 years (n = 518)
Age in years, median (IQR) 9.1 (4.0–15) 9.0 (4.0–14) 9.1 (4.0–14)
Male sex, % (95% CI) 52 (46–58) 53 (47–60) 53 (49–57)
Patients (n = 282)
Age in years, median (IQR) 30 (21–45) 28 (20–43) 28 (21–44)
Male sex, % (95% CI) 64 (55–72) 60 (52–68) 62 (56–67)
Completed secondary school, % (95% CI) 27 (20–35) 37 (29–45) 32 (27–38)
Unemployed before diagnosis, % (95% CI) 36 (28–44) 35 (27–43) 36 (30–41)
Number of days went to bed hungry in past month (i.e. food 
insecurity), mean (95% CI)
1.8 (1.1–2.5) 1.5 (0.9–2.1) 1.6 (1.2–2.1)
Sputum smear-positive,a % (95% CI) 71 (63–79) 68 (60–76) 70 (64–75)
Isoniazid-resistant tuberculosis only, % (95% CI) 6.7 (2.4–11) 8.2 (3.7–13) 7.4 (4.4–11)
MDR-TB, % (95% CI) 6.7 (2–11) 10.2 (5–15) 8.5 (5–12)
HIV-positive, % (95% CI) 3.7 (0.48–6.9) 5.4 (1.7–9.2) 4.6 (2.1–7.1)
Previous tuberculosis episode, % (95% CI) 18 (11–25) 27 (20–35) 23 (18–28)
Body mass index in kg/m2, mean (95% CI) 22 (21–23) 22 (21–22) 22 (21–22)
Households (n = 282)
Monthly household income in Peruvian soles, mean (95% CI) 1190 (1071–1309) 1271 (1127–1415) 1231 (1138–1325)
Number of people per room (i.e. crowding), mean (95% CI) 1.9 (1.7–2.1) 2.0 (1.8–2.2) 2.0 (1.8–2.1)
Poverty group,b % (95% CI)
    Poorest tercile 41 (32–49) 38 (30–46) 39 (34–45)
    Poor tercile 30 (23–38) 35 (27–42) 33 (27–38)
    Less-poor tercile 29 (21–37) 27 (20–34) 28 (23–33)
CI: confidence interval; HIV: human immunodeficiency virus; IQR: interquartile range; MDR-TB: multidrug-resistant tuberculosis; SD: standard deviation.
a  A sputum smear test result was defined as positive if acid alcohol-fast bacilli were observed by the Peruvian National Tuberculosis Programme reference laboratory 
or by our research team’s laboratory in a sputum sample obtained before tuberculosis treatment.
b  The level of household poverty was determined by combining socioeconomic variables into a composite index using principal component analysis, as previously 
described.29
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It is encouraging that the intervention 
also increased treatment initiation in 
younger contacts and contacts from 
poorer households, which suggests that 
its effect was equitable across age and 
social groups.
Nevertheless, although completion 
of 24 weeks of preventive therapy was 
nearly doubled in contacts from sup-
ported households, this increase was 
not statistically significant. The possible 
reasons are: (i) only a small number of 
contacts completed preventive therapy 
in each study arm and the study was 
not powered to assess this outcome; 
(ii) conditional cash transfers were not 
given monthly for adherence to preven-
tive therapy– they were made only when 
all eligible household contacts had com-
pleted therapy; and (iii) the cash trans-
fers were found not to completely defray 
direct out-of-pocket expenses because 
the financial burden of tuberculosis was 
high for households, as reported previ-
ously.27,45 Subsequently, in the CRESIPT 
study, economic support was increased 
to completely mitigate direct expenses 
and monthly conditional cash transfers 
were introduced for household contacts.
Our study provides evidence sup-
porting WHO’s End TB Strategy, which 
calls for the existing biomedical para-
digm of tuberculosis control to be 
supplemented by socioeconomic sup-
port interventions that address poverty 
and the other social factors principally 
responsible for the global tuberculosis 
epidemic.14 In addition to conditional 
cash transfers, which reduced food 
insecurity28 and improved access to 
health care, our intervention also in-
volved household visits and community 
meetings that provided education and 
information, helped reduce stigma and 
were empowering – a lack of knowledge 
about tuberculosis, being female and be-
ing marginalized are all risk factors for 
nonadherence to preventive therapy.46 
Although our study did not have the 
power to differentiate the effect of so-
cial and economic support, it has been 
reported that conditional cash transfers 
alone, without educational or social 
support, had only a limited impact on 
HIV-related outcomes.24
Our study had several limitations. 
First, the intention-to-treat analysis 
did not include treatment outcomes 
in patients still taking treatment at the 
final, 28-week follow-up, such as those 
with multidrug-resistant tuberculosis. 
Consequently, the proportion of pa-Ta
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tients whose treatment was successful 
was probably underestimated in both 
intervention and, perhaps to a greater 
extent, control households. How-
ever, the majority of our patients were 
HIV-negative, had drug-susceptible 
tuberculosis and should have been able 
to complete treatment by 28 weeks un-
less it was interrupted. Second, some 
households may have exaggerated the 
number of contacts to gain higher cash 
transfers. However, the number of 
contacts per household was similar for 
intervention and control households. 
Moreover, financial incentives were 
provided to households rather than 
individuals and only contacts declared 
before randomization and confirmed at 
a household visit were included. Third, 
patients and the study team were not 
blinded to the intervention and, in ad-
dition, a final conditional cash transfer 
was made to households in which the 
patient was cured and contacts com-
pleted preventive therapy. As a result, 
patients in the intervention group may 
have been more likely to attend their 
local health post to request confirma-
tion of a cure. Nevertheless, the study 
team did not encourage staff from the 
Peruvian National TB Programme to ask 
patients to confirm they had been cured 
and patients themselves, in feedback, 
reported that seeking confirmation was 
an empowering element of the interven-
tion.27 Furthermore, contacts’ initiation 
of preventive therapy and duration of 
preventive therapy taken was based on 
the number of weeks of isoniazid tablets 
collected from the health post and did 
not take actual adherence to preventive 
therapy into account. Finally, we were 
not able to separate the effects of the 
social and economic components of 
the intervention. To do so would have 
required a much larger sample size and 
been more expensive. In the future, 
larger studies could assess the differ-
ential impact of social and economic 
support on tuberculosis prevention and 
treatment and determine whether the 
findings are generalizable to patients 
with a high rate of HIV–tuberculosis 
coinfection or multidrug-resistant tu-
berculosis, patients in rural communi-
ties and those in low-income countries.
In conclusion, the socioeconomic 
support intervention developed in the 
initial phase of the CRESIPT project 
for application in an impoverished set-
ting was feasible and increased: (i) the 
proportion of household contacts of 
patients being treated for tuberculosis 
who initiated tuberculosis preven-
tive therapy; and (ii) the tuberculosis 
treatment success rate among patients. 
These findings highlight the need for 
larger-scale evaluations of the impact of 
socioeconomic support on tuberculosis 
care, prevention, control and, poten-
tially, elimination. ■
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ملخص
دراسة معشاة مضبطة حول الدعم االقتصادي االجتامعي هبدف تعزيز الوقاية من السل وعالجه يف بريو
الغرض تقييم مدى تأثري الدعم االجتامعي االقتصادي عىل طرح 
العالج الوقائي من السل لدى اأُلرس التي تتعامل مع مرىض السل 
ومدى تأثريه عىل نجاح عالج املرىض.
اأُلرس،  عىل  قائمة  عشوائية  عمياء،  غري  دراسة  إجراء  تم  الطريقة 
يونيو/حزيران  إىل   2014 فرباير/شباط  بني  ما  الفرتة  يف  مضبطة 
املرىض  الدراسة  هذه  وشملت  بريو.  يف  فقرًيا  حًيا   32 يف   2015
الذين خضعوا للعالج من السل وأفراد أرسهتم. وتم إسناد اأُلرس 
بشكٍل عشوائي إما إىل معيار الرعاية التي يوفرها الربنامج القومي 
ملواجهة السل يف بريو )الِشق اخلاص بالرقابة( أو نفس املعيار اخلاص 
بالرعاية باإلضافة إىل الدعم االقتصادي االجتامعي )الِشق اخلاص 
احلواالت  من  االجتامعي  االقتصادي  الدعم  ويتألف  بالتدخل(. 
أرسة،  لكل  أمريكًيا  دوالًرا   230 إىل  تصل  التي  الرشطية  النقدية 
معدالت  مقارنة  ومتت  املجتمعية.  واللقاءات  املنزلية،  والزيارات 
مبادرة العالج الوقائي من السل ونجاح العالج )أي إكامل العالج 
أو حتقيق الشفاء( يف الشقني املتعلقني بالرقابة والتدخل.
عىل  أرسة   )% 90 (  312 أصل  من   282 وافقت  إمجااًل،  النتائج 
املشاركة: 135 يف الِشق اخلاص بالتدخل، و147 يف الشق اخلاص 
ممن  باملرىض  حمتكني  أِشخاص   410 حوايل  هناك  وكان  بالرقابة. 
بالتدخل  الِشق اخلاص  43 % منهم يف  20 سنة: وبدأ  هم أقل من 
اخلاص  الشق  يف  منهم   % 25 مقابل  السل  من  الوقائي  العالج  يف 
بالتحكم )بنسبة احتامل معّدلة تبلغ: 2.2؛ بنسبة أرجحية مقدارها 
العالج  أن  العالج  لقصد  حتليل  وأوضح   .)4.1–1.1  :% 95 
سجل نجاًحا لدى 64 % من املرىض )135/87( يف الِشق اخلاص 
بالتدخل مقابل 53 % )147/78( يف الِشق اخلاص بالرقابة )نسبة 
األرجحية:  لنسبة  كمقدار  1.6؛  95 %  تبلغ:  معّدلة  غري  احتامل 
عدم  إىل  بالنظر  عادلة  التحسينات  تلك  وكانت   .)2.6–1.0
ارتباطها بفقر اأُلرس.
املخصص  االقتصادي  االجتامعي  الدعم  ساهم  االستنتاج 
السل  لداء  الوقائي  العالج  استيعاب  زيادة  يف  السل  داء  ملواجهة 
التقييم املجتمعي  ونجاح عالج داء السل، وجيري تقييمه يف إطار 
العشوائي ملرشوع الدعم االجتامعي االقتصادي ملواجهة داء السل 
 .)CRESIPT(
摘要
一项随机对照社会经济支持研究，用以改善秘鲁的结核病预防与治疗
目的 旨在评估社会经济支持对在结核病患者家庭接触
者中发起的结核病预防性治疗的影响以及对患者治疗
成功的影响。
方法 于 2014 年 2 月至 2015 年 6 月期间，在秘鲁
的 32 个贫民窟开展了一项非盲法家庭随机型对照研
究。 该项研究包括因结核病接受治疗的患者及其家庭
接触者。所有家庭随机分为接受秘鲁国家结核病项目
提供的标准护理的标准护理组 ( 对照组 )，和标准护理
加社会经济支持组（干预组）。社会经济支持包括每
户高达 230 美元的有条件现金转移支付、家庭探望及
社区会议。 对干预组及对照组的结核病预防性治疗的
发起率及患者治疗成功率（即，治愈或完成治疗）进
行了对比。
结果 312 户家庭中总计有 282 (90%) 户家庭同意参
加 ：135 户家庭为干预组，147 户家庭为对照组。其
中有 410 名接触者小于 20 岁 ： 干预组的结核病预
防性治疗发起率为 43%，对照组为 25%（调整后比
值 比，OR ： 2.2 ；95% 置 信 区 间，CI ： 1.1–4.1)。 一
项意向治疗分析显示，干预组患者的治疗成功率
为 64% (87/135)，对照组为 53% (78/147) （调整后 OR ： 
1.6; 95% CI: 1.0–2.6)。 这些改进均衡分布，与家庭贫
困程度无关。
结论 结核病专项社会经济支持干预提高了结核病
预防性治疗的接受率及结核病的治疗成功率，目
前正在接受结核病社会经济干预的社区随机化评
估 (CRESIPT) 项目的评估。
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Résumé
Une étude contrôlée randomisée de l’accompagnement socioéconomique pour améliorer la prévention et le traitement de la 
tuberculose au Pérou
Objectif  Évaluer l’impact de l’accompagnement socioéconomique sur 
le commencement du traitement préventif contre la tuberculose par les 
contacts familiaux des patients atteints de la maladie et sur la réussite 
du traitement pour les patients.
Méthodes  Une étude contrôlée, non aveugle, à répartition aléatoire des 
foyers a été réalisée entre février 2014 et juin 2015 dans 32 bidonvilles du 
Pérou. Elle portait sur des patients traités contre la tuberculose et leurs 
contacts familiaux. Les foyers ont été choisis de façon aléatoire pour 
recevoir soit les soins standards prévus par le programme national de 
lutte contre la tuberculose du Pérou (groupe témoin), soit les mêmes 
soins standards plus un accompagnement socioéconomique (groupe 
expérimental). L’accompagnement socioéconomique comprenait 
des transferts monétaires conditionnels pouvant atteindre 230 dollars 
des États-Unis par foyer, des visites à domicile et des réunions 
communautaires. Le taux de commencement du traitement préventif 
contre la tuberculose et le taux de réussite du traitement (guérison 
ou achèvement du traitement) ont été comparés entre le groupe 
expérimental et le groupe témoin.
Résultats  Au total, 282 foyers sur 312 (90%) ont accepté de participer: 
135 dans le groupe expérimental et 147 dans le groupe témoin. 
410 contacts avaient moins de 20 ans: dans le groupe expérimental, 
43% ont commencé un traitement préventif contre la tuberculose, 
contre 25% dans le groupe témoin (rapport des cotes ajusté (RC): 2,2; 
intervalle de confiance (IC) de 95%: 1,1-4,1). Une analyse par intention de 
traiter a montré la réussite du traitement chez 64% (87/135) des patients 
du groupe expérimental contre 53% (78/147) du groupe témoin (RC 
non ajusté: 1,6; IC 95%: 1,0-2,6). Ces améliorations étaient équitables et 
indépendantes de la pauvreté des foyers.
Conclusion  Une intervention d’accompagnement socioéconomique 
spécifiquement axé sur la tuberculose a permis d’augmenter la prise 
d’un traitement préventif contre la tuberculose ainsi que la réussite du 
traitement contre cette maladie. Elle est actuellement évaluée dans 
le cadre du projet CRESIPT (Community Randomized Evaluation of a 
Socioeconomic Intervention to Prevent TB).
Резюме
Рандомизированное контролируемое исследование социально-экономической поддержки с целью 
усиления профилактики и лечения туберкулеза в Перу
Цель Оценить, как влияет социально-экономическая поддержка 
на начало профилактического противотуберкулезного лечения 
членами семьи, контактирующими с больным, а также оценить 
вклад такой поддержки в успех лечения.
Методы  Открытое контролируемое исследование с 
рандомизацией семей было проведено в период между 
февралем 2014 года и июнем 2015 года в 32 трущобных 
поселениях в Перу. В исследование включались пациенты, 
получающие лечение от туберкулеза, и члены их семей, 
контактировавшие с ними. Семьям случайным образом назначали 
либо стандартное лечение, положенное в соответствии 
с национальной противотуберкулезной программой, 
осуществляемой в Перу (контрольная группа), либо такое же 
стандартное лечение в сочетании с социально-экономической 
поддержкой (экспериментальная группа). Социально-
экономическая поддержка включала выдачу денежных 
пособий при соблюдении определенных условий (в сумме до 
230 долларов США на семью), посещение семей и собрания 
общины. В контрольной группе и в экспериментальной группе 
сравнивались доли участников, начавших профилактическое 
противотуберкулезное лечение и успешно его завершивших (под 
успешным завершением подразумевалось излечение или 
завершение курса лечения).
Результаты Принять участие в исследовании согласились 
282 семьи из 312 (90%). В экспериментальную группу вошли 
135 семей, и 147 семей составили контрольную группу. 
В исследовании участвовали 410 контактирующих лиц 
в возрасте моложе 20 лет. В экспериментальной группе 
профилактическое противотуберкулезное лечение начали 
осуществлять 43% участников против 25% в контрольной 
группе (скорректированное отношение шансов, ОШ: 2,2; 95%-й 
доверительный интервал, ДИ: 1,1–4,2). Согласно результатам 
анализа по всем рандомизированным участникам, лечение было 
успешным в 64% случаев (87 из 135 семей) в экспериментальной 
группе и в 53% случаев (78 из 147 семей) в контрольной 
группе (нескорректированное ОШ: 1,6; 95%-й ДИ: 1,0–2,6). 
Улучшения наблюдались в равной мере и не зависели от того, 
насколько бедной была семья.
Вывод Социально-экономическая поддержка, специально 
ориентированная на помощь туберкулезным больным, 
увеличивает использование профилактического лечения 
и шанс успешного противотуберкулезного лечения и 
оценивается в рамках проекта оценки социально-экономических 
вмешательств для предотвращения туберкулеза с рандомизацией 
по сообществам (Community Randomized Evaluation of a 
Socioeconomic Intervention to Prevent TB, CRESIPT).
Resumen
Un estudio controlado aleatorizado de apoyo socioeconómico para mejorar la prevención y el tratamiento de la tuberculosis en Perú
Objetivo Evaluar el impacto del apoyo socioeconómico en la iniciación 
a la terapia preventiva contra la tuberculosis en contactos domésticos 
de pacientes con tuberculosis, así como en el éxito del tratamiento 
para los pacientes.
Métodos Entre febrero de 2014 y junio de 2015, se realizó un estudio 
controlado, aleatorizado, doméstico y no cegado en 32 barrios bajos 
de Perú. En este estudio se incluyeron pacientes que estaban siendo 
tratados contra la tuberculosis y sus contactos domésticos. Los hogares 
se asignaron de forma aleatoria a la atención estándar ofrecida por el 
programa nacional contra la tuberculosis de Perú (grupo de control) o 
bien a la misma atención estándar pero con un apoyo socioeconómico 
(grupo de intervención). El apoyo socioeconómico consistía en 
transferencias de efectivo condicionadas de hasta 230 dólares 
estadounidenses por hogar, visitas domésticas y reuniones comunitarias. 
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Se compararon los grupos de control y de intervención en cuanto a 
las tasas de iniciación a la terapia preventiva contra la tuberculosis y al 
éxito del tratamiento (es decir, la cura o la finalización del tratamiento).
Resultados En general, 282 de 312 (90%) hogares aceptaron participar: 
135 en el grupo de intervención y 147 en el grupo de control. Había 
410 contactos menores de 20 años: el 43% del grupo de intervención 
inició la terapia preventiva contra la tuberculosis, frente al 25% del grupo 
de control (coeficiente de posibilidades ajustado, CPa: 2,2; intervalo de 
confianza, IC, del 95%: 1,1–4,1). Un análisis de intención de tratar mostró 
que el tratamiento tuvo éxito en un 64% (87/135) de los pacientes del 
grupo de intervención, frente a un 53% (78/147) de los pacientes del 
grupo de control (CP no ajustado: 1,6; IC del 95%: 1,0–2,6). Estas mejoras 
fueron equitativas, independientemente de la pobreza del hogar.
Conclusión Una intervención de apoyo socioeconómico específica 
para la tuberculosis aumentó la aceptación de la terapia preventiva 
contra la tuberculosis y el éxito del tratamiento, y se está evaluando 
en el proyecto Community Randomized Evaluation of a Socioeconomic 
Intervention to Prevent TB (CRESIPT – Evaluación Aleatoria Comunitaria 
de una Intervención Socioeconómica para Prevenir la TB).
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